Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis

BACKGROUND: Checkpoint inhibitor–related pneumonitis (CIP) is a lethal immune-related adverse event. However, the development process of CIP, which may provide insight into more effective management, has not been extensively examined. METHODS: We conducted a multicenter retrospective analysis of 56...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Chengzhi, Yang, Yilin, Lin, Xinqing, Fang, Nianxin, Chen, Likun, Jiang, Juhong, Deng, Haiyi, Deng, Yu, Wan, Minghui, Qiu, Guihuan, Sun, Ni, Wu, Di, Long, Xiang, Zhong, Changhao, Xie, Xiaohong, Xie, Zhanhong, Liu, Ming, Ouyang, Ming, Qin, Yinyin, Petrella, Francesco, Fiorelli, Alfonso, Bravaccini, Sara, Kataoka, Yuki, Watanabe, Satoshi, Goto, Taichiro, Solli, Piergiorgio, Igai, Hitoshi, Saito, Yuichi, Tsoukalas, Nikolaos, Nakada, Takeo, Li, Shiyue, Chen, Rongchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364904/
https://www.ncbi.nlm.nih.gov/pubmed/35967342
http://dx.doi.org/10.3389/fimmu.2022.935779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364904/
https://www.ncbi.nlm.nih.gov/pubmed/35967342
http://dx.doi.org/10.3389/fimmu.2022.935779

Ejemplares similares